- To correlate clinical and biochemical cardiovascular risk factors to arterial wall 18-FDG uptake in large artery atherosclerotic lesions.- To correlate inflammatory markers to arterial wall 18-FDG uptake in large artery atherosclerotic lesions.
ID
Source
Brief title
Condition
- Arteriosclerosis, stenosis, vascular insufficiency and necrosis
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Correlation coefficients between clinical and biochemical cardiovascular risk
factors and inflammatory markers on the one hand and plaque inflammation
(measured as TBR) on the other hand.
Secondary outcome
n.a.
Background summary
Non-infectious inflammation plays a major role in the development and rupture
of atherosclerotic plaques. Atherosclerotic imaging traditionally focuses on
structural abnormalities only. Hybrid imaging of both structural and functional
abnormalities (inflammation) can be performed using positron emission
tomography /computed tomography using 18-FDG as a radiotracer. Previous
studies have shown increased arterial wall 18-FDG-uptake in symptomatic
atherosclerotic lesions, and increased uptake appears to predict clinical CVD
independent of structural abnormalities. Preliminary evidence suggests a
relationship between established traditional cardiovascular risk factors and
increased arterial wall 18-FDG-uptake. However, more data are needed to explore
the determinants of arterial wall 18 FDG uptake. Inflammatory parameters for
example, such as hsCRP and myeloperoxidase, may be associated with increased
inflammation.
Study objective
- To correlate clinical and biochemical cardiovascular risk factors to arterial
wall 18-FDG uptake in large artery atherosclerotic lesions.
- To correlate inflammatory markers to arterial wall 18-FDG uptake in large
artery atherosclerotic lesions.
Study design
Patients are seen once at the clinical research unit of the department of
internal medicine at the VU University Medical Center just prior to their
scheduled PET/CT scan. During this visit a cardiovascular risk profile will be
established by taking patient history, performing a brief physical examination
and drawing blood samples. Bivariate correlation analyses will be performed
between potential determinants of FDG uptake and the target to background ratio
(TBR = measure of plaque inflammation) in separate arterial regions.
Patients will be contacted 6 months after scanning to be asked about the
occurrence of cardiovascular events
Study burden and risks
Participating in this study will not lead to any increased risk or burden for
patients. There is no benefit for individual patients. For now the only benefit
is scientific.
De Boelelaan 1117
1081 HV Amsterdam
NL
De Boelelaan 1117
1081 HV Amsterdam
NL
Listed location countries
Age
Inclusion criteria
Being scheduled for 18-FDG-PET/CT examination at the VU university medical center
Exclusion criteria
- The use of immunosuppressive or cytotoxic medication at or 1 month prior to the scan.
- Inability to understand or unwillingness to provide informed consent.
- Plasma glucose > 11 mmol/l at time of PET/CT-scan.
- Suspected vasculitis as indication for PET/CT.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL32957.029.10 |